L'obésité est l'un des plus grands défis de santé publique du 21ème siècle et est considérée comme un facteur de risque majeur pour la santé. L'obésité est responsable de l'apparition de divers troubles, notamment du diabète, des maladies cardiovasculaires et de certains cancers. Le tissu adipeux (TA) est un organe endocrine très actif qui a une activité sécrétoire intense produisant un assortiment de plus de 600 facteurs qui ont des activités biologiques variées. Certains de ces facteurs sont appelés adipocytokines et font l'objet d'un intérêt particulier dans les recherches récentes sur le métabolisme et les pathologies associées. De nombreuses données sur les adipocytokines suggèrent fortement que le tissu adipeux est un élément clé dans le développement d'une inflammation chronique. De nombreuses maladies neurodégénératives chroniques telles que la sclérose latérale amyotrophique, la maladie d'Alzheimer et la maladie de Parkinson ont été associées à une inflammation du système nerveux central (SNC), dans lequel la microglie et les astrocytes (cellules gliales) jouent un rôle déterminant. L'autotaxin (ATX) et l'adiponectine (ADIPO) sont des médiateurs sécrétées par le TA. Le rôle de ces médiateurs dans les activités métaboliques a été bien étudié, mais leur rôle potentiel ainsi que les mécanismes précis dans la vulnérabilité du CNS restent à déterminer. Ici, nous proposons d'utiliser, in vivo, deux stimuli inflammatoires distincts le lipopolysaccharide (LPS) et le triméthylétain (TMT) pour caractériser l'expression de médiateurs de l'inflammation du SNC chez la souris. Une injection intrapéritonéale (ip) aiguë de LPS (100 μg/kg de poids corporel) mime une infection bactérienne Gram négative, tandis que l'injection ip aiguë de TMT (2 mg/kg de poids corporel), induit une neurodégénérescence hippocampique. Les microglies et les astrocytes sont les principales sources de facteurs inflammatoires dans le cerveau. Afin de rechercher, in vitro, le rôle de l'ATX et de l'ADIPO sur ces cellules dans un état inflammatoire et de stress oxydatif, nous avons généré des tansfectants stables sur-exprimant l'ATX dans des cellules microgliales murines (BV2) et l'ADIPO dans des cellules astrocytaires murines (CLTT). Les clones BV2 et CLTT surexprimant ces facteurs ont été traitées avec du LPS (1 μg/ml) et du H2O2 (100μM). Nos résultats in vivo ont démontré que l'ATX et l'ADIPO sont exprimés dans le cerveau et que le LPS pourrait induire une réponse neuroinflammatoire transitoire dans trois régions distinctes du cerveau l'hippocampe (HIP), le cortex (COR) et le cervelet (CER). Il a été également constaté qu'à cette dose modérée de 100μg de LPS / kg de poids corporel de la souris, la microglie et les astrocytes ne sont pas activés dans le cerveau (Projet-1). Nos résultats in vitro démontrent les effets anti-inflammatoires de l'ATX dans les cellules microgliales observables par la baisse d'expression des marqueurs d'activation microgliale (CD11b, CD14, CD80 et CD86) et d'expression et de production de cytokines pro-inflammatoires (TNF-α et IL-6) (Project-2). Nous avons montré que l'ADIPO a un rôle anti-oxydant dans les astrocytes via l'atténuation significative de ROS, une inhibition d'enzymes pro-oxydantes (iNOS et la COX-2) et une régulation positive d'enzymes anti-oxydantes (SOD et CAT) (Projet-3). Dans l'ensemble, ces résultats suggèrent qu'une inflammation périphérique induite par une infection ne provoque pas de neurodégénérescence (à moins d'une infection importante), mais pourrait sensibiliser les cellules gliales et augmenter leur réponse à la stimulation suivante. L'ATX et l'ADIPO pourraient jouer un rôle dans la régulation de la neuroinflammation en régulant l'activation gliale dans un contexte de stress. Des travaux supplémentaires seront nécessaires afin de mieux comprendre les mécanismes moléculaires régulant l'inflammation du SNC et aboutir à de nouvelles stratégies thérapeutiques pour combattre les maladies neurodégénératives. / Globally obesity is one of the greatest public health challenges of 21st century, and is considered a major health risk factor. Obesity is responsible for the onset of various kinds of disorders including diabetes, cardiovascular diseases and cancer. Adipose tissue (AT) is a highly active endocrine organ which has intense secretory activity producing an assortment of over 600 factors that have versatile biological activities. Some of these factors are named adipocytokines and have gain an intensive focus on current metabolic and disease recent research. Accumulating data on adipocytokine research strongly suggest that adipose tissue is the key player in promoting chronic inflammation. Many chronic neurodegenerative diseases such as Amyotrophic lateral sclerosis, Alzheimer’s and Parkinson’s diseases have been associated with inflammation in the Central Nervous System (CNS) in which microglia and astrocytes (glial cells) play a decisive role. Autotaxin (ATX) and Adiponectin (ADIPO) are mediators secreted by the AT. The role of these mediators in metabolic activities have been well studied but the potential role of these adipocyte secreted factors and its precise mechanisms in CNS vulnerability remains to be determined. Here we used, in vivo, two distinct inflammatory stimuli, lipopolysaccharide (LPS) and trimethyltin (TMT), to characterize the expression of inflammatory mediators in mouse CNS. Acute intraperitoneal (ip) injection of LPS (100μg/Kg bwt) mimics gram negative bacterial infection, while acute ip injection of organometal TMT (2mg/kg bwt), induces hippocampal neurodegeneration. Microglia and astrocytes are the major source of inflammatory factors in the brain. To investigate, in vitro, the role of ATX and ADIPO in inflammatory and oxidative stress condition, we generated stable over-expressing transfectant in murine microglia BV2 cells for ATX and murine astrocyte CLTT cells for ADIPO. BV2 and CLTT stably transfected overexpressing clones were treated with LPS (1 μg/mL) and H2O2 (100μM). Our in vivo results demonstrated that ATX and ADIPO were expressed in the brain and LPS induced a transient neuroinflammatory response in three distinct regions of the brain hippocampus (HIP), cortex (COR) and cerebellum (CER). Besides this it was also found that with this mild dosage of 100 μg LPS/Kg bwt of mice, microglia and astrocytes were not activated in the brain (Project-1). Our in vitro results authenticate the anti-inflammatory effects of ATX in microglial cells demonstrated by the downregulation of microglial activation markers (CD11b, CD14, CD80 and CD86) and pro-inflammatory cytokine expression and secretion (TNF-α and IL-6) (Project-2). Likewise, ADIPO put forth its anti-oxidant role in astrocyte cells mediated via significant mitigation of ROS, and as well by the significant down and upregulation of pro-oxidative inducible nitric oxide synthase (iNOS) and cyclooxygenase-2(COX-2) and anti-oxidative enzymes mRNA expression levels superoxide dismutase (SOD) and catalase (CAT) respectively (Project-3). Overall these results suggest that peripheral inflammation induced by infection will not induce neurodegeneration (unless a massive infection) but could prime the glial cells and make them more responsive to the next stimulation. ATX and ADIPO may play a role in the regulation of neuroinflammation by regulating glial activation in stressed situations. Further investigations will be needed to better understand the molecular mechanisms regulating brain inflammation and lead to new therapeutic strategies to combat neurodegenerative diseases.

L’obésité est responsable de diverses complications médicales, notamment respiratoires. Elle favorise l’apparition de maladies bronchiques chroniques (asthme, BPCO) et complique leur prise en charge. Elle s’accompagne de troubles respiratoires du sommeil et augmente la susceptibilité aux infections respiratoires.Le tissu adipocytaire est désormais reconnu comme un tissu hormonal, source de nombreux médiateurs dont font partie les adipokines, cytokines produites principalement par les adipocytes. Parmi celles-ci, l’adiponectine (APN) est une protéine de 30kDa qui peut s’associer en multimères de plus ou moins haut poids moléculaire. Ses taux circulants sont élevés mais sa concentration sérique diminue avec le gain de poids.L’adiponectine est impliquée dans les phénomènes d’immunorégulation associés aux modifications nutritionnelles et également dans le développement pulmonaire. Mais le rôle pro ou anti-inflammatoire de l’APN est toujours un sujet à débat. L’association entre les taux sériques d’APN et la survenue de maladies bronchiques n’est pas clairement démontrée chez l’homme.Nous nous sommes intéressés au rôle que joue l’APN au sein du système respiratoire, dans la régulation du fonctionnement des macrophages et cellules épithéliales bronchiques. Nous avons plus particulièrement étudié l’effet de l’APN sur la sécrétion de cytokines par ces deux types cellulaires.Nous disposons de pièces opératoires pulmonaires de patients opérés pour un cancer bronchique, à partir desquelles nous réalisons des cultures primaires d’explants de parenchyme, de macrophages pulmonaires ou de cellules épithéliales bronchiques et nous disséquons des anneaux bronchiques.Nous avons montré qu’il existait une production d’APN in situ par du tissu pulmonaire humain et que cette production était corrélée, à l’instar de la forme circulante, au poids du patient. Nous avons vérifié que les récepteurs à l’APN (AdipoR1 et AdipR2) étaient tous les deux exprimés par des macrophages pulmonaires, des explants de bronches et des cellules épithéliales bronchiques.Nous avons soumis les macrophages pulmonaires humains à un traitement par de l’APN à différentes concentrations (3-10-30 microg/ml) avant de les stimuler par du LPS (10 ng/ml ou Poly I:C 10 ng/ml) ou d’IL-4 (10 ng/ml). Nous avons montré que l’adiponectine diminuait la sécrétion des cytokines M1 induites par le LPS et le Poly I:C (IL6, CCL3, CCL4, CCL5, CXCL8, TNF). tout comme celles des cytokines M2 induites par l’IL-4 (CCL13, CCL18, CCL22). L'adipoRon, agoniste synthétique des récepteurs de l'adiponectine, a montré les mêmes effets que la protéine recombinante.Nous avons comparé avec l’effet d’autres adipokines : la leptine à sa plus grande concentration (1000 ng/ml) induisait la production de cytokines de type M1 (IL6, CCL3, CCL4, CCL5, TNFa) par des macrophages non stimulés alors que la visfatine et la chémérine n’avaient aucun effet sur la production de cytokines par les macrophages.Seule l’adiponectine a démontré un effet sur les cellules épithéliales bronchiques, en modulant de façon opposée la production de certaines cytokines : diminution de la sécrétion de CXCL1 et CCL2 en situation basale et après traitement par TNF (50 ng/ml) mais augmentation de celle d’IL6 et CXCL8 en situation basale.Nous avons complété ce travail par des expériences sur la régulation du tonus bronchique par les adipokines, en utilisant des anneaux bronchiques dans des cuves à organes isolées. Ces résultats ont fait l'objet d’un dépôt de brevet européen.Ces travaux sont les premiers à s’intéresser à l’effet de l’APN et de l’AdipoRon sur un modèle de culture primaire de macrophages et cellules épithéliales bronchiques humains. L’APN est capable de moduler la polarisation de ces cellules. Les adipokines régulent aussile tonus bronchique. Les adipokines sont essentielles à la compréhension du retentissement pulmonaire de l’obésité. / Obesity promotes the development of chronic bronchial diseases (asthma, COPD) and complicates their management, induces sleep breathing disorders and increases susceptibility to respiratory infections. Adipocytea are a source of mediator production including adipokines. Among these, adiponectin (APN) is a 30kDa protein that can associate in multimers of variable molecular weight. It circulates at high level but its serum concentration decreases with weight gain. APN is involved in immunoregulation and pulmonary development. But the pro or anti-inflammatory role of the APN is still a matter for debate. The association between serum levels of APN and the occurrence of bronchial diseases is not clearly demonstrated in humans. We explored the role of adipokines within the respiratory system. In particular, we studied the effect of the APN on the production of cytokines by pulmonary macrophages and bronchial epithelial cells. We obtained lung specimens from patients operated for carcinoma, from which we carried out primary cultures of parenchymal explants, pulmonary macrophages or bronchial epithelial cells and we also prepared bronchial rings for study in organ bath. We have revealed an in situ production of APN by human lung tissue, which is correlated with patient weight. We have verified that APN receptors (AdipoR1 and AdipR2) were both expressed by pulmonary macrophages, bronchial explants, and bronchial epithelial cells. We have treated human lung macrophages with APN (3-10-30 μg/ml) before stimulation with LPS (10 ng / ml) or Poly I: C (10 ng/ml) or IL-4 (10 ng/ml).We have shown that the APN decreased the production of M1 cytokines induced by LPS and Poly I: C (IL-6, CCL3, CCL4, CCL5, CXCL8, TNFa) as well as those of M2 cytokines induced by IL-4 (CCL13, CCL18, CCL22). AdipoRon, a synthetic adiponectin receptor agonist, exhibited the same effects as the recombinant protein. In comparison, leptin at its highest concentration (1000 ng/ml) induced the production of M1-type cytokines (IL-6, CCL3, CCL4, CCL5, TNF-α) by unstimulated macrophages whereas visfatin and chemerin did not reveal any effect on cytokine production by macrophages. Only APN demonstrated an effect on bronchial epithelial cells: decreasing the production of CXCL1 and CCL2 at basal state and after stimulationwith TNF (50 ng / ml) but increasing production of IL6, CCL20 and CXCL8 in the basal situation. We have completed this work by experiments on the regulation of bronchial tone by adipokines, using bronchial rings in isolated organ baths. These results have been the subject of a European patent application. This work is the first looking at the effect of APN and AdipoRon on primary human pulmonary macrophages and bronchial epithelial cells. APN is able to modulate the polarization of these cells. Adipokines are essential for understanding the respiratory burden of obesity.

Background: Adiponectin circulates in the blood in three different multimer isoforms, of which the high molecular weight form (HMW) is presumed to mediate insulin sensitivity. We examined whether adiponectin oligomer distribution is associated with aging and type 2 diabetes (T2D) in octogenarians without characteristic features of metabolic syndrome. Methods: The study included 154 octogenarians (58 men, 96 women), 24 normoglycemic middle-aged controls (11 men, 13 women; mean age 44 years), and 33 middle-aged individuals (14 men, 19 women; mean age 55 years) with T2D. Based on oral glucose tolerance test 62 octogenarians had normal, 63 impaired glucose tolerance, and 29 octogenarians had newly detected T2D. Serum adiponectin multimer isoforms were measured after overnight fast by enzyme-linked immunosorbent assays. Results:Compared to the normoglycemic middle-aged control group, male normoglycemic octogenarians revealed significantly higher total adiponectin and all adiponectin isoforms. The same was true for females with the exception of low molecular weight (LMW) adiponectin, which was not statistically higher in octogenarians. Male and female octogenarians with T2D had significantly higher levels of total, HMW, and middle molecular weight (MMW) adiponectin, but not LMW adiponectin, than middle-aged individuals with T2D. Female, but not male, octogenarians revealed significantly lower total adiponectin than normoglycemic octogenarians. Compared with normoglycemic octogenarians, male and female octogenarians with T2D were characterized by significantly lower LMW adiponectin. In male and female octogenarians, total adiponectin and all multimer isoforms were directly correlated with HDL cholesterol. LMW adiponectin in octogenarians of both sexes was inversely correlated with glucose level at 2-hour oral glucose tolerance test. Conclusions: Serum levels of total adiponectin as well as its HMW and MMW isoforms were significantly higher in octogenarians with normoglycemia or T2D than in corresponding middle-aged control groups. In male and female octogenarians without metabolic syndrome, T2D was associated with lower LMW adiponectin, while the HMW and MMW isoforms were not statistically different. / Dieser Beitrag ist mit Zustimmung des Rechteinhabers aufgrund einer (DFG-geförderten) Allianz- bzw. Nationallizenz frei zugänglich.

Background: Inflammation is proposed to play a role in the development of Alzheimer's disease, and may also be involved in the pathogenesis of mild cognitive impairment (MCI). This study examined the association of inflammatory markers in serum or plasma with prevalent MCI and MCI subtypes in a population-based sample. Methods: Olmsted County, MN, residents aged 70-89 years on October 1, 2004, were evaluated using the Clinical Dementia Rating Scale, a neurological evaluation, and neuropsychological testing. Information ascertained for each participant was reviewed by an expert panel of neuropsychologists, physicians, and nurses, and a diagnosis of normal cognition, MCI, or dementia was made by consensus. C-reactive protein (CRP), interleukin-6 (IL-6), tumor necrosis alpha (TNFα), and adiponectin were measured at baseline. Results: Among 313 subjects with MCI and 1570 cognitively normal subjects, a CRP level in the upper quartile (>3.3 mg/L) was significantly associated with MCI (odds ratio [OR], 1.42; 95% confidence interval [CI], 1.00-2.01) and with nonamnestic MCI (OR, 2.05; 95% CI, 1.12-3.78) after adjusting for age, sex, and years of education. However, there was no association with amnestic MCI (OR, 1.21; 95% CI, 0.81-1.82). No association was observed with the other inflammatory markers. Conclusions: Plasma CRP is associated with prevalent MCI and with nonamnestic MCI in elderly, nondemented persons in a population-based setting. These findings suggest the involvement of inflammation in the pathogenesis of MCI.

Physiological Reports published by Wiley Periodicals, Inc. on behalf of The Physiological Society and the American Physiological Society. C1q/TNF-related protein 3 (CTRP3) is a relatively novel adipose tissue-derived cytokine (adipokine) which has been linked to improved glucose regulation and insulin sensitivity. However, the relationship between circulating CTRP3 levels and diabetes is controversial. CTRP3 can circulate in different oligomeric complexes: trimeric, hexameric, and high molecular weight (HMW) oligomeric complexes. However, the concentration of the different oligomeric complexes in human disease states has not been previously investigated. Therefore, the purpose of this study was to compare the levels of different oligomeric complexes of CTRP3 between type 2 diabetic and nondiabetic individuals. Additionally, the association between the oligomeric complexes and other serum factors was examined. CTRP3 primarily circulates in the HMW complex (>50%) and the hexametric multimer, with no CTRP3 detected in the trimeric complex or as a monomer. Further, no differences were observed in total, hexameric, or HMW CTRP3 levels regardless of diabetic status. Surprisingly, HMW CTRP3 was found to be positively correlated with circulating triglyceride levels. Combined, these data suggest that CTRP3 is associated with triglyceride regulation, not diabetic status. These data may explain some of the discrepancies in the literature as elevated triglyceride levels are often detected in patients with obesity and type 2 diabetes.

京都大学 / 0048 / 新制・課程博士 / 博士(医学) / 甲第19400号 / 医博第4051号 / 新制||医||1012(附属図書館) / 32425 / 京都大学大学院医学研究科医学専攻 / (主査)教授 横出 正之, 教授 福原 俊一, 教授 山下 潤 / 学位規則第4条第1項該当 / Doctor of Medical Science / Kyoto University / DFAM

No description available.

Type 2 diabetes mellitus (T2DM) is classified as a metabolic disorder characterized by hyperglycemia that results from defects in insulin action and/or secretion, and currently affects 8.3% of the US population according to the CDC’s 2011 National Diabetes Fact Sheet. Several contributing factors have been identified to development of this disease. Published evidence indicates type 2 diabetes mellitus (T2DM) patients display lower overall paraoxonase activity and that this may be partially due to genetic variations in the paraoxonase-1 (PON-1) gene. Some bioaccumulative organochlorine (OC) pesticides have been shown to contribute to increased T2DM prevalence. In addition, these OC compound levels have been associated with alterations in adipocyte cytokine levels as well as increased inflammatory markers. Three hundred blood samples with clinical and demographic information were obtained from two US Air Force hospitals. A total of 151 non-diabetics and 149 T2DM subjects were evaluated for PON-1 activity, PON-1 Q192R and L55M genetic polymorphisms, OC compound concentrations, inflammatory marker levels and adipokine concentrations. PON-1 activity, using diazoxon as the substrate, was decreased in the T2DM subjects. Some of the PON-1 genetic polymorphisms tested were also associated with decreased PON-1 activity. OC compound levels were increased in the T2DM subjects. The non-diabetic subjects possessing elevated DDE and trans-nonachlor were associated with increased inflammation, a common hallmark of early T2DM development. Additionally, elevated OC levels were seen in association with altered adipokine concentrations. Overall, a decrease in the antioxidant properties of PON-1 as well as factors contributing to chronic low level inflammation such as elevated OC plasma concentration appear to be significant contributors to T2DM prevalence in the population studied.

Thesis (MSc. Medical Science (Chemical Pathology)) -- University of Limpopo, 2017 / Obesity has been associated with dyslipidaemia (increased levels of triglycerides, total cholesterol and low levels of HDL-C together with small dense lipoprotein particles) in the absence of metabolic disorders such as, type 2 diabetes mellitus and inflammation. Since community based studies in South Africa reported that obesity is more common in women, and rural Africans have a more favourable lipid profile compared to their White counterparts, the current study investigated the association of obesity in women without metabolic disorders with lipid levels and changes in proportions of small and large LDL and HDL particles. Methods The present study was part of the project “Prevention, Control and Integrated Management of Chronic Disease in a rural area, South Africa”. A total of 521 women participated in the above project. After excluding people with diabetes mellitus, insulin resistance and inflammation, 308 women were left and of these 67 were obese. Sixty seven ages matched, randomly selected non-obese women served as controls. Anthropometry variables as well as systolic and diastolic blood pressures were measured and the WHO steps questionnaire was administered to collect information on medication, lifestyle and diseases. Fasting blood levels of total cholesterol, HDL C, triglyceride, adiponectin, CRP, glucose and insulin were measured. Proportions of small and large HDL and LDL particles were determined. Results There was no significant difference in TC, TG and LDL-C levels (p=0.558, 0.087 and 0.948) between obese and non-obese women or between women with increased waist circumference (WC) and those with normal WC. The HDL-C concentration was significantly lower in obese women compared to women with non- obese (p=0.001). The lipid ratios TC/HDL-C and Apo B-100/Apo A-I were significantly higher in obese women than those with non- obese (p=0.013 and p=0.006) respectively. The same phenomenon was observed in women with xv increased waist circumference (p=0.001** and p=0.025* respectively). Adiponectin levels were significantly lower in obese women compared to non-obese women (p=0.004**) and in women with increased waist circumference compared to those with normal waist circumference (p=0.016*). The proportions of small dense HDL and LDL lipoprotein particles were similar in obese and non-obese women. Both obese and abdominally obese women had significantly higher odds ratios of low levels of HDL-C and elevated Apo B-100/Apo A-I. Adiponectin was a significant predictor of elevated TC and TG in both obese and abdominally obese women while BMI was a significant predictor of low HDL-C in obese women. Waist circumference was a significant predictor of low HDL-C in abdominally obese women. Conclusion In the current study, obesity in women was significantly associated with lipid abnormalities such as low HDL-C levels, raised lipid ratios (TC/HDL-C and Apo B 100/Apo A-I) and low levels of adiponectin, after excluding metabolic disorders / VLIR

No description available.